LOCALIZED MYOCARDIAL INJECTION METHOD FOR TREATING ISCHEMIC MYOCARDIUM
This invention relates to a method of treating ischemic or diseased myocardium by injecting a therapeutic agent, such as a gene, protein, cell or drug, into normal myocardium, preferably adjacent to an ischemic zone in the heart of a subject. The method is useful for inducing angiogenesis and collateral blood vessel formation to improve cardiac function in subjects with ischemic heart disease. The method can also be used to promote tissue regeneration in such subjects.
1 . A method for delivering a therapeutic nucleic acid to an ischemic or diseased heart, comprising intramyocardially delivering a therapeutically-effective amount of said therapeutic nucleic acid to normal tissue in said heart.
2 . The method of claim 1 , wherein the therapeutic nucleic acid is delivered to normal tissue adjacent to ischemic tissue or diseased tissue.
3 . The method of claim 1 or 2 , wherein the therapeutic nucleic acid is injected at multiple sites in the normal tissue.
4 . The method of claims 1 , wherein the therapeutic nucleic acid encodes a protein.
5 . The method of claim 4 , wherein the protein is selected from the group consisting of FGF-1, FGF-2, FGF-5, VEGF, VEGF165, HIF-1, PDGF-1, PDGF-2, DEL1, angiopoietin, HGF, MCP-1, eNOS, and iNOS.
6 - 8 . (canceled)
9 . The method of claim 6 , wherein the nucleic acid is delivered as RNA, DNA, plasmid or a viral vector.
10 . The method of claim 9 , wherein the viral vector is an adenovirus vector or an adeno-associated virus vector.
11 . The method of claim 10 , wherein said RNA, DNA, plasmid or a viral vector is in a liposome.
12 - 14 . (canceled)
15 . The method of claim 1 , wherein a therapeutically effective amount is further defined as an amount to stimulate collateral blood vessel formation in the myocardium.
16 . (canceled)
17 . The method of claim 1 , wherein a therapeutically effective amount is further defined as an amount to induce angiogenesis in the myocardium which comprises intramyocardially delivering an angiogenic factor to normal tissue in an ischemic heart of a subject in an amount sufficient to induce angiogenesis.
18 . (canceled)
19 . The method of claim 1 , wherein a therapeutically effective amount is further defined as an amount to improve contractile function in an ischemic heart.
20 . (canceled)
21 . The method of claim 1 , wherein a therapeutically effective amount is further defined as an amount to promote tissue regeneration in an ischemic or diseased heart.
22 - 25 . (canceled)
26 . The method of claim 4 wherein said protein is a growth factor.
27 . (canceled)
28 . The method of claim 1 , wherein said nucleic acid comprises a coding sequence for a protein operatively linked to a promoter effective to induce expression of said protein in a cardiac muscle cell.
29 . The method of claim 28 , wherein said promoter is tissue-specific.
30 . The method of claim 29 , wherein the tissue-specific promoter is selected from the group consisting of the promoters of cTNC, MHCα, MHCβ, MLC 2v , NppA, and CARP.
31 . (canceled)
32 . The method of claim 29 , wherein the tissue-specific promoter is selected from the group consisting of the promoters of MHCα, MHCβ, MLC 2v , NppA, and CARP.
33 - 51 . (canceled)
52 . The method of claim 1 , wherein said delivering results in an amelioration of symptoms of ischemia indicated by increased transmural blood flow in the myocardium at rest or under stress conditions, by collateral blood vessel formation, by improved contractile function or by regeneration of myocardial tissue.
53 . The method of claim 1 , wherein said delivering results in an amelioration of one or more symptoms of ischemia as indicated by reduced chest pain or reduced shortness of breath.
54 . The method of claim 1 , wherein said delivering is by a catheter, a a needle, a needle-free injector, or a channeling device.
55 . The method of claim 54 , wherein said catheter is a stiletto catheter.